From a story on axios.com by Caitlin Owens headlined “The potential downsides of new blockbuster obesity drugs”:

Even as encouraging data fuels hype around a new class of obesity drugs, regulators and experts are racing to better understand possible health risks that are still emerging in a market projected to be worth tens of billions of dollars.

Why it matters: Weight-loss drugs like Ozempic have quickly become a cultural phenomenon and a source of hope for people with obesity and related health conditions. But recent reports of potential side effects, including suicidal thoughts, have raised concerns.